The challenge of evaluating annual mammography screening for young women with a family history of breast cancer

Journal of Medical Screening

Volumn 13, Issue 4, 2006, Pages 177-182

  Gabe, Rhian ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FAMILY HISTORY; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; MAMMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY; TUMOR VOLUME;

EID: 33846033585     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/096914130601300404     Document Type: Article

References (20)

1. Smith RA, Duffy SW, Gabe R, et al. The randomized trials of breast cancer screening: what have we learned? Radiol Clin N Am 2004;42:793-806
2. Duffy SW, Tabar L, Smith RA, et al. Risk of breast cancer and risks with breast cancer: the relationship of histologic type with epidemiology, disease progression and survival. Semin Breast Dis 2;1999:292-300
3. Thull DL, Vogel VG. Recognition and management of hereditary breast cancer syndromes. Oncologist 2004;9:13-24
4. MARIBS Study Group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78
5. IARC. Breast Cancer Screening. Lyon: IARC Press, 2002
6. Mackay J, Rogers C, Fielder H, et al. Development of a protocol for evaluation of mammographic surveillance services in women under 50 with a family history of breast cancer. J Epidemiol Biostat 2001;6:365-9; discussion 371-5
7. Moss S, Waller M, Anderson TJ, et al. Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. Br J Cancer 2005;92:955-60
8. Tabar L, Fagerberg G, Duffy SW, et al. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin N Am 1992;30:187-210
9. Duffy SW, Day NE, Tabar L, et al. Markov models of breast tumor progression: some age-specific results. J Natl Cancer Inst Monogr 1997;22:93-7
10. Organizing Committee and Collaborators FM. Breast-cancer screening with mammography in women aged 40-49 years. Swedish Cancer Society and the Swedish National Board of Health and Welfare. Int J Cancer 1996;68:693-9
11. Balslev I, Axelsson CK, Zedeler K, et al. The nottin Gham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 1994;32:281-90
12. Chen HH, Duffy SW, Tabar L, et al. Markov chain models for progression of breast cancer. Part 2: prediction of outcomes for different screening regimes. J Epidemiol Commun Health 1997;2:25-35
13. Chen HH, Thurfjell E, Duffy SW, et al. Evaluation by Markov chain models of a non-randomised breast cancer screening programme in women aged under 50 years in Sweden. J Epidemiol Commun Health 1998;52:329-335
14. Chen HH, Duffy SW, Tabar L, et al. Markov chain models for progression of breast cancer. Part 1: tumour attributes and the preclinical screen-detectable phase. J Epidemiol Commun Health 1997;2:9-23
15. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-30
16. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003;40:807-14
17. Launoy G, Duffy SW, Prevost TC, et al. Detection of cancer, sensitivity of the test and sensitivity of the screening program. Rev Epidemiol Sante Publ 1998;46:420-6
18. Myles J, Duffy S, Nixon R, et al. Initial results of a study into the effectiveness of breast cancer screening in a population identified to be at high risk. Rev Epidemiol Sante Publ 2001;49:471-5
19. Duffy SW, Agbaje O, Tabar L, et al. Estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res 2006;7:258-65
20. Cuzick J. Aromatase inhibitors in prevention - data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 2003;163:96-103; discussion 264-6